[1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA:Cancer J Clin, 2015, 65(2):87-108.  doi: 10.3322/caac.21262
[2] Sun XP, Dong X, Lin L, et al. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer[J]. FEBS J, 2014, 281(1):115-128. DOI:10.1111/febs.12577.
[3] Spick C, Herrmann K, Czernin J. 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer:Evidence from Studies on More Than 2300 Patients[J]. J Nucl Med, 2016, 57(3):420-430. DOI:10.2967/jnumed.115.158808.
[4] Wu CX, Zhu ZH. Diagnosis and evaluation of gastric cancer by positron emission tomography[J]. World J Gastroenterol, 2014, 20(16):4574-4585. DOI:10.3748/wjg.v20.i16.4574.
[5] Smyth E, Schöder H, Strong VE, et al. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer[J]. Cancer, 2012, 118(22):5481-5488. DOI:10.1002/cncr.27550.
[6] Yun M. Imaging of Gastric Cancer Metabolism Using 18F-FDG PET/CT[J]. J Gastric Cancer, 2014, 14(1):1-6. DOI:10.5230/jgc. 2014. 14.1.1.
[7] Redondo-Cerezo E, Martínez-Cara JG, Jiménez-Rosales R, et al. Endoscopic ultrasound in gastric cancer staging before and after neoadjuvant chemotherapy. A comparison with PET-CT in a clinical series[J]. United European Gastroenterol J, 2017, 5(5):641-647. DOI:10.1177/2050640616684697.
[8]

Altini C, Niccoli AA, Di PA, et al. 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography[J/OL]. Medicine (Baltimore), 2015, 94(20): e864[2018-01-08]. https://www.ncbi.nlm.nih.gov/pubmed/25997066. DOI: 10.1097/MD.0000000000000864.

[9]

Ma Q, Xin J, Zhao Z, et al. Value of 18F-FDG PET/CT in the diagnosis of primary gastric cancer via stomach distension[J/OL]. Eur J Radiol, 2013, 82(6): e302-306[2018-01-08]. https://www.ncbi.nlm.nih.gov/pubmed/23434453. DOI: 10.1016/j.ejrad.2013.01.021.

[10] Youn SH, Seo KW, Lee SH, et al. 18F-2-Deoxy-2-Fluoro-D-Glucose Positron Emission Tomography:Computed Tomography for Preoperative Staging in Gastric Cancer Patients[J]. J Gastric Cancer, 2012, 12(3):179-186. DOI:10.5230/jgc.2012.12.3.179.
[11] Minamimoto R, Senda M, Jinnouchi S, et al. Performance profile of a FDG-PET cancer screening program for detecting gastric cancer:results from a nationwide Japanese survey[J]. Jpn J Radiol, 2014, 32(5):253-259. DOI:10.1007/s11604-014-0294-0.
[12] Inoue K, Goto R, Okada K, et al. A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity[J]. Ann Nucl Med, 2009, 23(7):643-649. DOI:10.1007/s12149-009-0286-9.
[13] Lee SJ, Lee WW, Yoon HJ, et al. Regional PET/CT after water gastric inflation for evaluating loco-regional disease of gastric cancer[J]. Eur J Radiol, 2013, 82(6):935-942. DOI:10.1016/j.ejrad.2013.01.014.
[14] Kim SJ, Cho YS, Moon SH, et al. Primary Tumor 18F-FDG Avidity Affects the Performance of 18F-FDG PET/CT for Detecting Gastric Cancer Recurrence[J]. J Nucl Med, 2016, 57(4):544-550. DOI:10.2967/jnumed.115.163295.
[15] Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA:Cancer J Clin, 2011, 61(2):69-90.  doi: 10.3322/caac.v61:2
[16] Na SJ, o JH, Park JM, et al. Prognostic value of metabolic parameters on preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stageⅢ gastric cancer[J]. Oncotarget, 2016, 7(39):63968-63980. DOI:10.18632/oncotarget.11574.
[17] Kaneko Y, Murray WK, Link E, et al. Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancer[J]. J Nucl Med, 2015, 56(4):523-529. DOI:10.2967/jnumed.114.150946.
[18] Ha TK, Choi YY, Song SY, et al. F18-fluorodeoxyglucose-positron emission tomography and computed tomography is not accurate in preoperative staging of gastric cancer[J]. J Korean Surg Soc, 2011, 81(2):104-110. DOI:10.4174/jkss.2011.81.2.104.
[19] Yoon NR, Park JM, Jung HS, et al.[Usefulness of 18F-fluoro-2-deoxyglucose positron emission tomography in evaluation of gastric cancer stage] [J]. Korean J Gastroenterol, 2012, 59(5):347-353.  doi: 10.4166/kjg.2012.59.5.347
[20]

Stabile IAA, Telegrafo M, Lucarelli NM, et al. Comparison between CT Net enhancement and PET/CT SUV for N staging of gastric cancer: A case series[J/OL]. Ann Med Surg (Lond), 2017, 21: 1-6[2018-01-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519227. DOI: 10.1016/j.amsu.2017.07.033.

[21] Choi JI, Joo I, Lee JM. State-of-the-art preoperative staging of gastric cancer by MDCT and magnetic resonance imaging[J]. World J Gastroenterol, 2014, 20(16):4546-4557. DOI:10.3748/wjg.v20.i16. 4546.
[22]

Okumura Y, Aikou S, Onoyama H, et al. Evaluation of 18F-FDG uptake for detecting lymph node metastasis of gastric cancer: a prospective pilot study for one-to-one comparison of radiation dose and pathological findings[J/OL]. World J Surg Oncol, 2015, 13: 327[2018-01-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4667411. DOI: 10.1186/s12957-015-0743-y.

[23] Oh HH, Lee SE, Choi IS, et al. The peak-standardized uptake value (P-SUV) by preoperative positron emission tomography-computed tomography (PET-CT) is a useful indicator of lymph node metastasis in gastric cancer[J]. J Surg Oncol, 2011, 104(5):530-533. DOI:10.1002/jso.21985.
[24] Wang Z, Chen JQ. Imaging in assessing hepatic and peritoneal metastases of gastric cancer:a systematic review[J]. BMC Gastroenterol, 2011, 11:19. DOI:10.1186/1471-230X-11-19.
[25] Kawanaka Y, Kitajima K, Fukushima K, et al. Added value of pretreatment 18F-FDG PET/CT for staging of advanced gastric cancer:Comparison with contrast-enhanced MDCT[J]. Eur J Radiol, 2016, 85(5):989-995. DOI:10.1016/j.ejrad.2016.03.003.
[26] Choi JY, Shim KN, Kim SE, et al. The clinical value of 18F-fluorodeoxyglucose uptake on positron emission tomography/computed tomography for predicting regional lymph node metastasis and non-curative surgery in primary gastric carcinoma[J]. Korean J Gastroenterol, 2014, 64(6):340-347.  doi: 10.4166/kjg.2014.64.6.340
[27] Kim DW, Park SA, Kim CG. Detecting the recurrence of gastric cancer after curative resection:comparison of FDG PET/CT and contrast-enhanced abdominal CT[J]. J Korean Med Sci, 2011, 26(7):875-880. DOI:10.3346/jkms.2011.26.7.875.
[28] Ma DW, Kim JH, Jeon TJ, et al. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for the evaluation of bone metastasis in patients with gastric cancer[J]. Dig Liver Dis, 2013, 45(9):769-775. DOI:10.1016/j.dld.2013.02.009.
[29] Lee JH, Son SY, Lee CM, et al. Factors predicting peritoneal recurrence in advanced gastric cancer:implication for adjuvant intraperitoneal chemotherapy[J]. Gastric Cancer, 2014, 17(3):529-536. DOI:10.1007/s10120-013-0306-2.
[30] Kang WM, Meng QB, Yu JC, et al. Factors associated with early recurrence after curative surgery for gastric cancer[J]. World J Gastroenterol, 2015, 21(19):5934-5940. DOI:10.3748/wjg.v21.i19. 5934.
[31] Lee JW, Lee SM, Son MW, et al. Diagnostic performance of FDG PET/CT for surveillance in asymptomatic gastric cancer patients after curative surgical resection[J]. Eur J Nucl Med Mol Imaging, 2016, 43(5):881-888. DOI:10.1007/s00259-015-3249-5.
[32] Wu LM, Hu JN, Hua J, et al. 18F-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer:a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2012, 27(3):472-480. DOI:10.1111/j.1440-1746.2011.06919.x.
[33] Lee JW, Lee SM, Lee MS, et al. Role of 18F-FDG PET/CT in the prediction of gastric cancer recurrence after curative surgical resection[J]. Eur J Nucl Med Mol Imaging, 2012, 39(9):1425-1434. DOI:10.1007/s00259-012-2164-2.
[34] Sharma P, Singh H, Suman SK, et al. 18F-FDG PET-CT for detecting recurrent gastric adenocarcinoma:results from a Non-Oriental Asian population[J]. Nucl Med Commun, 2012, 33(9):960-966. DOI:10.1097/MNM.0b013e328355b694.
[35] Zou H, Zhao Y. 18FDG PET-CT for detecting gastric cancer recurrence after surgical resection:a meta-analysis[J]. Surg Oncol, 2013, 22(3):162-166. DOI:10.1016/j.suronc.2013.05.001.
[36] Lee DY, Lee CH, Seo MJ, et al. Performance of 18F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients[J]. Ann Nucl Med, 2014, 28(8):789-795. DOI:10.1007/s12149-014-0871-4.
[37] Choi BW, Zeon SK, Kim SH, et al. Significance of SUV on Follow-up 18F FDG PET at the Anastomotic Site of Gastroduodenostomy after Distal Subtotal Gastrectomy in Patients with Gastric Cancer[J]. Nucl Med Mol Imaging, 2011, 45(4):285-290. DOI:10.1007/s13139-011-0105-9.
[38] Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer:descriptive epidemiology, risk factors, screening, and prevention[J]. Cancer Epidemiol Biomarkers Prev, 2014, 23(5):700-713. DOI:10.1158/1055-9965.EPI-13-1057.
[39] Takahashi T, Saikawa Y, Kitagawa Y. Gastric cancer:current status of diagnosis and treatment[J]. Cancers (Basel), 2013, 5(1):48-63. DOI:10.3390/cancers5010048.
[40] Lee JW, Jo K, Cho A, et al. Relationship Between 18F-FDG Uptake on PET and Recurrence Patterns After Curative Surgical Resection in Patients with Advanced Gastric Cancer[J]. J Nucl Med, 2015, 56(10):1494-1500. DOI:10.2967/jnumed.115.160580.
[41]

Sun X, Wang J, Liu J, et al. Albumin concentrations plus neutrophil lymphocyte ratios for predicting overall survival after curative resection for gastric cancer[J/OL]. Onco Targets Ther, 2016, 9: 4661-4669[2018-01-07]. https://www.ncbi.nlm.nih/gov/pmc/articles/PMC4973773. DOI: 10.2147/OTT.S108631.

[42] Grabinska K, Pelak M, Wydmanski J, et al. Prognostic value and clinical correlations of 18-fluorodeoxyglucose metabolism quantifiers in gastric cancer[J]. World J Gastroenterol, 2015, 21(19):5901-5909. DOI:10.3748/wjg.v21.i19.5901.
[43] Ock CY, Kim TY, Lee KH, et al. Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications[J]. Gastric Cancer, 2016, 19(2):421-430. DOI:10.1007/s10120-015-0504-1.
[44] Wu Z, Zhao J, Gao P, et al. Prognostic value of pretreatment standardized uptake value of F-18-fluorodeoxyglucose PET in patients with gastric cancer:a meta-analysis[J]. BMC Cancer, 2017, 17(1):275. DOI:10.1186/s12885-017-3271-z.
[45] Park JS, Lee N, Beom SH, et al. The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status[J]. Gastric Cancer, 2018, 21(2):213-224. DOI:10.1007/s10120-017-0739-0.
[46] Coupe NA, Karikios D, Chong S, et al. Metabolic information on staging FDG-PET-CT as a prognostic tool in the evaluation of 97 patients with gastric cancer[J]. Ann Nucl Med, 2014, 28(2):128-135. DOI:10.1007/s12149-013-0791-8.
[47]

Song BI, Kim HW, Won KS, et al. Preoperative Standardized Uptake Value of Metastatic Lymph Nodes Measured by 18F-FDG PET/CT Improves the Prediction of Prognosis in Gastric Cancer[J/OL]. Medicine (Baltimore), 2015, 94(26): e1037[2018-01-07]. https://www.ncbi.nlm.nih.gov/pubmed/26131811. DOI: 0.1097/MD.0000000000001037.